Evidence map›Paper›PMID 20231081›Full record

ArticleEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2010

Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms.

L A Carvalho, B A Garner, T Dew, H Fazakerley, C M Pariante

Open access · greenAbstract readComparative Study
In one paragraph

Article in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Avicenna journal of phytomedicine · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

L A CarvalhoSection of Perinatal Psychiatry & Stress, Psychiatry and Immunology Laboratory, King's College London, Institute of Psychiatry, London, UK. l.carvalho@kcl.ac.uk
B A Garner
T Dew
H Fazakerley
C M Pariante
King's College London · GBKing's College School · GBUniversity of Melbourne · AU

Funding

Medical Research Council G108/603Medical Research Council G108/603(68006)
6 · The paper itself

Abstract

Clinical studies have demonstrated an impairment of glucocorticoid receptor (GR)-mediated negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis in patients with major depression (GR resistance), and its resolution by antidepressant treatment. Recently, we showed that this impairment is indeed due to a dysfunction of GR in depressed patients (Carvalho et al., 2009), and that the ability of the antidepressant clomipramine to decrease GR function in peripheral blood cells is impaired in patients with major depression who are clinically resistant to treatment (Carvalho et al. 2008). To further investigate the effect of antidepressants on GR function in humans, we have compared the effect of the antidepressants clomipramine, amytriptiline, sertraline, paroxetine and venlafaxine, and of the antipsychotics, haloperidol and risperidone, on GR function in peripheral blood cells from healthy volunteers (n=33). GR function was measured by glucocorticoid inhibition of lypopolysaccharide (LPS)-stimulated interleukin-6 (IL-6) levels. Compared to vehicle-treated cells, all antidepressants inhibited dexamethasone (DEX, 10-100nM) inhibition of LPS-stimulated IL-6 levels (p values ranging from 0.007 to 0.1). This effect was specific to antidepressants, as antipsychotics had no effect on DEX-inhibition of LPS-stimulated IL-6 levels. The phosphodiesterase (PDE) type 4 inhibitor, rolipram, potentiated the effect of antidepressants on GR function, while the GR antagonist, RU-486, inhibited the effect of antidepressants on GR function. These findings indicate that the effect of antidepressants on GR function are specific for this class of psychotropic drugs, and involve second messenger pathways relevant to GR function and inflammation. Furthermore, it also points towards a possible mechanism by which one maybe able to overcome treatment-resistant depression. Research in this field will lead to new insights into the pathophysiology and treatment of affective disorders.

Indexed as

AdultAntidepressive AgentsAntidepressive Agents, TricyclicAntipsychotic AgentsCyclic AMPDexamethasoneFemaleGlucocorticoidsHormone AntagonistsHumansInterleukin-6LipopolysaccharidesMaleMifepristonePhosphodiesterase InhibitorsReceptors, GlucocorticoidAntidepressive AgentsAntidepressive Agents, TricyclicAntipsychotic AgentsCyclic AMPDexamethasoneGlucocorticoidsHormone AntagonistsInterleukin-6LipopolysaccharidesMifepristonePhosphodiesterase InhibitorsReceptors, GlucocorticoidRolipramSelective Serotonin Reuptake Inhibitors

Identifiers

PMID20231081
PMCPMC2982744
OpenAlexW2039741113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.